| B43-PAP | B43-PAP immunotoxin |
| BA | Betulinic acid |
| BAF | Triazinate |
| BAM HCl | Boanmycin hydrochloride |
| BAY 73-4506 monohydrate | Regorafenib hydrate |
| BB-10901 | Lorvotuzumab mertansine |
| BB-12/LGG | Bifidobacterium animalis/Lactobacillus rhamnosus probiotic supplement |
| BBB | Blood-brain barrier |
| BBBD | Blood-brain barrier disruption |
| BBD | Babaodan capsule; Borderline breast disease |
| BBIC | Bowman-Birk inhibitor concentrate |
| BBSKE | Ethaselen |
| BC-819/PEI | BC-819 plasmid/polyethylenimine complex |
| BC8-SA | anti-CD45 BC8 monoclonal antibody-streptavidin conjugate |
| BCAA supplement | Branched-chain amino acid supplement |
| BCG | Bacillus Calmette-Guérin |
| BC-IL | Recombinant leukocyte interleukin |
| BCL2 | B-cell leukemia/lymphoma 2 protein |
| BCM | Carbendazim |
| BCNS | Basal cell nevus syndrome; Gorlin syndrome; Nevoid basal cell carcinoma syndrome |
| BCNU | Carmustine |
| BCOP | Board certified oncology pharmacy specialist |
| BCRP | Breast cancer resistance protein |
| BCV | Brincidofovir |
| BCX-1777 | Forodesine hydrochloride |
| BDC | Bellini duct carcinoma |
| BDCS | Bazex-Dupré-Christol syndrome |
| BEACOPP | BEACOPP regimen |
| BEN | Benzaldehyde dimethane sulfonate |
| benazepril HCl | Benazepril hydrochloride |
| BEP | BEP regimen |
| BG | O6-benzylguanine |
| b-GLUC | Beta-glucan |
| Bi213 MOAB M195 | Bismuth Bi213 monoclonal antibody M195 |
| BIC | Imidazole mustard |
| BiCNU | Carmustine |
| BIDA | Amonafide dihydrochloride |
| BI-RADS | Breast Imaging Reporting and Data System |
| BiTE | Bispecific T-cell engager |
| BJD | Bushen-Jianpi decoction |
| BJ-Se | High-selenium Brassica juncea |
| BL22 | BL22 immunotoxin |
| BLEO | Bleomycin |
| BLEO/DOX/DTIC/VBL | ABVD regimen |
| BMD | Bone density; Bone mass; Bone mineral density |
| BMF | Acoustic coupling fluid |
| BM-hMSC-D24 | Tasadenoturev-infected allogeneic bone marrow-derived mesenchymal stem cells |
| BMI | Body mass index |
| BMS-182751 | Satraplatin |
| BMS-214662 | Farnesyltransferase inhibitor BMS-214662 |
| BMS-247550 | Ixabepilone; Ixempra |
| BMS-354825 | Dasatinib; Sprycel |
| BMT | Bone marrow transplant |
| BMTP-11 | Bone metastasis targeting peptide-11 |
| BNCT | Boron neutron capture therapy |
| BON | Bisphosphonate-associated osteonecrosis |
| BP1-7-KLH | emepepimut-S |
| BPA | Boron phenylalanine |
| BPA-F | Boronophenylalanine-fructose complex |
| BPD | Borderline personality disorder |
| BPDCN | Blastic plasmacytoid dendritic cell neoplasm |
| BPD-MA | Verteporfin |
| BPH | Benign prostatic hyperplasia; Benign prostatic hypertrophy; Enlarged prostate |
| BPU | Benzoylphenylurea |
| BR96-DOX | BR96-doxorubicin immunoconjugate |
| BR-DIM | Oral microencapsulated diindolylmethane |
| BRYO | Bryostatin 1 |
| BsAb 2B1 | Bispecific antibody 2B1 |
| BSE | Breast self-exam |
| BSH | Sodium borocaptate |
| BSI-201 | Iniparib |
| BSO | Buthionine sulfoximine |
| BSRL | Buserelin |
| BSS | Brooke-Spiegler syndrome |
| B-TGDR | Beta-thioguanine deoxyriboside |
| BTX-A | Botulinum toxin type A |
| BuMel | Busulfan/melphalan regimen |
| BUN | Blood urea nitrogen |
| BUS | Busulfan |
| BVDU | Bromovinyl-deoxyuridine |
| BW-B759U | Ganciclovir |
| BXM | Baloxavir marboxil |